Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study

Author:Naismith, Robert   Zivadinov, Robert   Morrow, Sarah   Bass, Ann   Obeidat, Ahmed   Riser, Emily   Wray, Sibyl   Cristofanilli, Massimiliano   Riolo, Jon   Thorpe, Andrew   Chaudhry, Burhan   Mohiuddin, Kamran   Cheng, Chun-Yen   DeLuca, John   

Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

Topic:Multiple Sclerosis  

Program Number:P10.014  

Author Institution:Washington University School of Medicine, St Louis, Missouri, Saint Louis, MO  Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, Buffalo, NY  London Health Sciences Centre, University Hospital, University of Western Ontario, London, Ontario, Canada, and Department of Clinical Neurological Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, London, ON, Canada  Neurology Center of San Antonio, San Antonio, Texas, San Antonio, TX  Department of Neurology, The Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, WI  Alabama Neurology Associates, Birmingham, Alabama, Birmingham, AL  Hope Neurology MS Center, Knoxville, Tennessee, Knoxville, TN  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey, Amherst, NY  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ  

Fulminant Paraneoplastic Neuromyelitis Optica Spectrum Disorder (NMOSD) with Triple-negative, Aquaporin-4-positive Breast Cancer

Effect of Applying Inclusion and Exclusion Criteria of Phase III Complement Inhibitor and FCRN Inhibitor Trials to Acetylcholine Receptor-positive Generalized Myasthenia Gravis Patients in Routine Clinical Care